Corporate news: Pfizer (PFE) issues FY2025 guidance

Pfizer (PFE) reaffirmed its guidance for FY2024, seeing EPS of $2.75-2.95 versus analysts’ consensus estimate of $2.91 and revenues of $61-64 bln versus analysts’ consensus estimate of $62.89 bln.

The company also issued in-line guidance for FY2025, seeing EPS of $2.80-3.00 versus analysts’ consensus estimate of $2.86 and revenues of $61-64 bln versus analysts’ consensus estimate of $63.22 bln.

PFE rose to $25.88 (+2.50%) in pre-market trading.